Sign In
Buy DARE
$2.05
-0.0900 (-4.21%)
At Close: Jun 03, 2026
Published data shows that Ovaprene was safe and effective in a postcoital test study of 33 women Pivotal Phase 3 contraceptive efficacy clinical study of Ovaprene currently enrolling Ovaprene has the
Daré Bioscience, Inc. (DARE) Q4 2023 Earnings Call Transcript
08:47pm, Thursday, 28'th Mar 2024
Daré Bioscience, Inc. (DARE) Q4 2023 Earnings Call Transcript
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update
08:00am, Thursday, 28'th Mar 2024
2023 Highlights and Anticipated 2024 Milestones XACIATO™ (clindamycin phosphate) vaginal gel 2% is available by prescription in the United States to treat bacterial vaginosis under license agreement
Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024
08:00am, Thursday, 21'st Mar 2024
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at
This overlooked corner of women's health could be a $350 billion market opportunity
02:33pm, Friday, 15'th Mar 2024
Menopause is among the female health conditions with the highest unmet need and has 'enormous potential for innovative treatments,' according to McKinsey.
There are no FDA-approved treatments for female sexual arousal disorder There are no FDA-approved treatments for female sexual arousal disorder
Daré Bioscience Announces Executive Team and Board of Directors Changes
04:30pm, Friday, 26'th Jan 2024
SAN DIEGO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced changes in company management which includes the retirement
Daré Bioscience Announces Grant to Support Biotherapeutic Product Development
08:00am, Wednesday, 17'th Jan 2024
Grant funds support activities that will aid the ultimate development of bacteria-based biotherapeutic products designed to benefit women and newborns Grant funds support activities that will aid the
Strategic Process Underway to Explore Partnering Opportunities for Additional Indications such as with GLP-1s for Obesity and Metabolic Disorders and Other Conditions Requiring Precise, Prolonged Trea
Daré Bioscience Secures $12 million in Royalty-backed Investment Structure
08:00am, Tuesday, 26'th Dec 2023
$5 million at closing and up to $7 million of additional committed funding $5 million at closing and up to $7 million of additional committed funding
Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study
08:00am, Wednesday, 20'th Dec 2023
Data Support Continued Clinical Development of DARE-PDM1 and its Potential as a First-in-Category Treatment for Primary Dysmenorrhea Data Support Continued Clinical Development of DARE-PDM1 and its Po
DARE-PTB1 is being developed as a treatment to reduce the risk of preterm birth, for which there are no FDA-approved treatment options
Daré Bioscience, Inc. (DARE) Q3 2023 Earnings Call Transcript
09:56pm, Thursday, 09'th Nov 2023
Daré Bioscience, Inc. (NASDAQ:DARE ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Sabrina Martucci Johnson - President and CEO John Fair - Chief Commercial Office
Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update
08:00am, Thursday, 09'th Nov 2023
Conference Call and Webcast Today at 4:30 p.m. ET What to Expect for the Remainder of 2023 XACIATO™: receipt of $1.8 million triggered by achievement of first commercial milestone under license agre
Daré Bioscience to Participate in Three November Conferences
08:00am, Monday, 06'th Nov 2023
SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that the company's President and CEO, Sabrina Martucci Jo
